| Literature DB >> 26902456 |
Zan Ding1, Fuhua Pi2, Shengchao Zhang3, Wenya Dong1, Ye Wen1, Jiang Wu3, Qingying Zhang1.
Abstract
The existing definitions of metabolic syndrome (MetS) may not be fully appropriate for the Shantou population because of ethnic and regional differences. We sought to establish a 95% multivariate medical reference range (MMRR) model for diagnosing MetS in Shantou adults and to evaluate the prevalence of MetS by the MMRR, JCDCG (the Chinese Guidelines), and International Diabetes Federation (IDF) criteria. A total of 4,580 participants were recruited in Shantou, southern China. We developed a MMRR model based on the combinatorial indicatrixes method for three categorized indicatrixes. According to the developed MMRR criteria, men (women) in Shantou have MetS by meeting 3 or more of the following: waist circumference ≥89 (81) cm; triglycerides level ≥1.73 (1.64) mmol/L; high-density lipoprotein cholesterol level ≤1.07 (1.05) mmol/L; blood pressure ≥138/89 (136/85) mmHg; and fasting plasma glucose ≥5.8 (5.7) mmol/L. The agreement of the MMRR with JCDCG and IDF criteria was "substantial" (both κ > 0.68), but the recommended reference values and proportion of individual components of MetS defined by the 3 criteria differed. The population-based MMRR criteria may be appropriate for diagnosing MetS in Shantou population and the model might be useful for generalization to other geographic regions.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26902456 PMCID: PMC4763302 DOI: 10.1038/srep22210
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Definitions of metabolic syndrome (MetS) by the MMRR, JCDCG, and IDF diagnostic criteria.
| Components of MetS | MMRR | JCDCG | IDF | |||
|---|---|---|---|---|---|---|
| Men | Women | Men | Women | Men | Women | |
| WC, cm | ≥89 | ≥81 | >90 | >85 | ≥90 | ≥80 |
| TG, mmol/L | ≥1.73 or specific treatment of TG abnormality | ≥1.64 or specific treatment of TG abnormality | ≥1.70 | ≥1.70 | ≥1.7 or specific treatment of TG abnormality | ≥1.7 or specific treatment of TG abnormality |
| HDL-C, mmol/L | ≤1.07 or specific treatment of HDL-C abnormality | ≤1.05 or specific treatment of HDL-C abnormality | <1.04 | <1.04 | <1.03 or specific treatment of HDL-C abnormality | <1.29 or specific treatment of HDL-C abnormality |
| BP, mmHg | SBP ≥ 138 or DBP ≥ 89 or treatment of previously diagnosed hypertension | SBP ≥ 136 or DBP ≥ 85 or treatment of previously diagnosed hypertension | SBP ≥ 130 or DBP ≥ 85 | SBP ≥ 130 or DBP ≥ 85 | SBP ≥ 130 or DBP ≥ 85 or treatment of previously diagnosed hypertension | SBP ≥ 130 or DBP ≥ 85 or treatment of previously diagnosed hypertension |
| FPG, mmol/L | ≥ 5.8 or previously diagnosed type 2 diabetes | ≥ 5.7 or previously diagnosed type 2 diabetes | ≥ 6.1 or 2-h plasma glucose ≥ 7.8 or diagnosed diabetes | ≥ 6.1 or 2-h plasma glucose ≥ 7.8 or diagnosed diabetes | ≥ 5.6 or previously diagnosed type 2 diabetes | ≥ 5.6 or previously diagnosed type 2 diabetes |
| Required | ≥ 3 risk factors | ≥ 3 risk factors | ≥ 3 risk factors | ≥ 3 risk factors | central obesity plus ≥ 2 other risk factors | central obesity plus ≥ 2 other risk factors |
MMRR, multivariate medical reference range; JCDCG, Chinese Joint Committee for Developing Chinese Guidelines; IDF, International Diabetes Federation; WC, waist circumference; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; SBP/DBP, systolic/diastolic blood pressure; FPG, fasting plasma glucose.
Characteristics of the study population in the Shantou region of southern China.
| Variables | Total (n = 4,580) | Men (n = 3,062) | Women (n = 1,518) |
|---|---|---|---|
| Age, years | 44.0 (36.0–57.0) | 43.0 (35.0–54.0) | 47.0 (37.0–60.0)* |
| WC, cm | 81.0 (74.0–87.0) | 82.8 (77.0–88.0) | 76.0 (69.0–83.0)* |
| TG, mmol/L | 1.27 (0.89–1.93) | 1.35 (0.96–2.09) | 1.08 (0.76–1.63)* |
| HDL-C, mmol/L | 1.31 (1.13–1.50) | 1.28 (1.11–1.46) | 1.36 (1.16–1.58)* |
| SBP, mmHg | 121.0 (110.0–134.4) | 122.0 (112.0–134.0) | 120.0 (110.0–135.0)* |
| DBP, mmHg | 80.0 (70.0–85.0) | 80.0 (72.0–86.0) | 77.0 (70.0–82.0)* |
| FPG, mmol/L | 5.07 (4.70–5.53) | 5.07 (4.70–5.51) | 5.08 (4.70–5.59) |
Data are median (interquartile range [IQR]).
*P < 0.001 comparing women with men by the Mann–Whitney U test.
WC, waist circumference; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; SBP/DBP, systolic/diastolic blood pressure; FPG, fasting plasma glucose.
Figure 1Overall crude prevalence and overlap of metabolic syndrome (MetS) by the JCDCG, MMRR, and IDF criteria among Shantou adults.
Standardized prevalence of MetS and its individual components by the MMRR, JCDCG, and IDF criteria.
| MMRR (%) | JCDCG (%) | IDF (%) | |||||||
| Men* | Women* | Total† | Men* | Women* | Total† | Men* | Women* | Total† | |
| Individual components of MetS | |||||||||
| Elevated WC | 21.5¶ | 28.7‡¶ | 25.0¶ | 15.9§ | 14.3§ | 15.1§ | 18.7 | 32.5‡ | 25.5 |
| Elevated TG | 30.4‡ | 19.8 | 25.2 | 31.1‡ | 18.5 | 24.9 | 31.1‡ | 18.5 | 24.9 |
| Reduced HDL-C | 19.2‡¶ | 13.9¶ | 16.6¶ | 13.9‡§ | 11.2§ | 12.6§ | 12.8 | 40.0‡ | 26.3 |
| Elevated SBP and/or DBP | 25.3¶ | 24.5¶ | 24.9¶ | 42.5‡§ | 29.6§ | 36.1§ | 42.5‡ | 29.6 | 36.1 |
| Elevated FPG | 14.4¶ | 16.1¶ | 15.2¶ | 10.3§ | 9.7§ | 10.0§ | 19.6 | 19.7 | 19.7 |
| MetS | 14.2¶ | 12.9¶ | 13.5¶ | 13.8‡ | 9.4§ | 11.6§ | 11.2 | 15.7‡ | 13.4 |
| Number of metabolic abnormalities | |||||||||
| 0 | 40.1 | 43.2 | 41.6 | 36.5 | 51.2 | 43.8 | 36.7 | 32.7 | 34.7 |
| 1 | 28.7 | 28.4 | 28.5 | 31.5 | 26.8 | 29.2 | 32.5 | 40.1 | 36.2 |
| 2 | 17.1 | 15.6 | 16.3 | 18.2 | 12.6 | 15.4 | 20.6 | 16.4 | 18.6 |
| 3 | 9.6 | 8.3 | 8.9 | 9.7 | 6.6 | 8.2 | 8.6 | 8.3 | 8.5 |
| 4 | 3.8 | 4.2 | 4.0 | 3.6 | 2.5 | 3.1 | 1.6 | 2.5 | 2.0 |
| 5 | 0.8 | 0.4 | 0.6 | 0.5 | 0.3 | 0.4 | 0 | 0 | 0 |
*Age-standardized prevalence rates.
†Age-standardized and sex-standardized prevalence rates. Standardization was conducted with the 2010 Chinese National Census Population by the direct method.
‡P < 0.001, significantly higher than for the other sex.
¶P < 0.001, the standardized proportions were significantly different among the MMRR, JCDCG, and IDF criteria.
§P < 0.001 comparing the JCDCG with the MMRR criteria. ÿP < 0.001 comparing the IDF with the MMRR criteria.
MetS, metabolic syndrome; MMRR, multivariate medical reference range; JCDCG, Chinese Joint Committee for Developing Chinese Guidelines; IDF, International Diabetes Federation; WC, waist circumference; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; SBP/DBP, systolic/diastolic blood pressure; FPG, fasting plasma glucose.
Figure 2Age-specific percentage of MetS in men, women, and total subjects (sex-standardized) in the Shantou region of southern China by the MMRR (a), JCDCG (b), and IDF (c) criteria.
Agreement between the MMRR and JCDCG, and MMRR and IDF criteria.
| Criteria | MMRR | ||||||
|---|---|---|---|---|---|---|---|
| Observed agreement (%) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Kappa index (95% CI) | Judgment for agreement | |
| JCDCG | |||||||
| Total | 94.48 | 87.60 | 95.62 | 76.88 | 97.89 | 0.79 (0.76, 0.81)* | substantial |
| Men | 94.94 | 85.31 | 96.65 | 81.95 | 97.36 | 0.81 (0.78, 0.84)* | almost perfect |
| Women | 93.54 | 93.16 | 93.60 | 67.56 | 98.96 | 0.75 (0.70, 0.80)* | substantial |
| IDF | |||||||
| Total | 91.88 | 76.80 | 94.57 | 71.64 | 95.80 | 0.69 (0.66, 0.72)* | substantial |
| Men | 92.33 | 82.41 | 93.73 | 65.15 | 97.40 | 0.68 (0.65, 0.72)* | substantial |
| Women | 90.97 | 69.97 | 96.43 | 83.59 | 92.52 | 0.71 (0.66, 0.75)* | substantial |
*P < 0.001 testing the null hypothesis that the extent of agreement is same as random ( = 0).
MMRR, multivariate medical reference range; JCDCG, Chinese Joint Committee for Developing Chinese Guidelines; IDF, International Diabetes Federation; PPV, positive predictive value; NPV, negative predictive value; 95% CI, 95% confidence interval.